Expression changes of serum miR-455-3p and miR-106b-5p in patients with chronic obstructive pulmonary disease and their clinical significance

doi:10.3969/j.issn.1673-8640.2026.08.008

Abstract

Abstract:

Objective To investigate the changes in serum miR-455-3p and miR-106b-5p expressions in patients with chronic obstructive pulmonary disease（COPD）and their clinical significance. Methods A total of 109 COPD patients（COPD group）and 90 healthy subjects（healthy control group）were enrolled from Qinghai Red Cross Hospital from March 2022 to March 2024. Based on disease severity，COPD patients were classified into stable phase group（47 cases）and acute exacerbation of chronic obstructive pulmonary disease（AECOPD）group（62 cases）. The clinical data were collected，and serum levels of miR-455-3p and miR-106b-5p were determined along with lung function parameters including forced expiratory volume in one second（FEV₁），forced vital capacity（FVC），peak expiratory flow（PEF）and FEV₁/FVC ratio. Pearson correlation analysis was used to assess the relationship between serum miR-455-3p and miR-106b-5p levels and lung function indicators. Logistic regression analysis was performed to identify risk factors for AECOPD. Receiver operating characteristic（ROC）curves were used to evaluate the diagnostic performance of serum miR-455-3p and miR-106b-5p for AECOPD. Results The relative expression levels of serum miR-455-3p and miR-106b-5p were lower in COPD group compared to healthy control group（P<0.001）. Compared with stable phase group，the AECOPD group showed reduced relative expression of miR-455-3p and miR-106b-5p，as well as lower FEV₁，FVC，FEV₁/FVC ratio and PEF（P<0.01）. Serum expressions of miR-455-3p and miR-106b-5p in COPD patients were positively correlated with lung function parameters（FEV₁，FVC，FEV₁/FVC，PEF）（P<0.001）. Reduced expressions of miR-455-3p and miR-106b-5p，as well as decreased FEV₁，FVC，FEV₁/FVC and PEF levels，were all independent risk factors for AECOPD（P<0.05）. The areas under curves（AUC） of miR-455-3p，miR-106b-5p single and combined determinations were 0.733，0.842 and 0.894，respectively. Conclusions Serum miR-455-3p and miR-106b-5p are downregulated in COPD patients and correlated with lung function parameters. The combined determination has high diagnostic value for AECOPD.

Key words: MicroRNA-455-3p, MicroRNA-106b-5p, Lung function, Chronic obstructive pulmonary disease

CLC Number:

R446.7

YANG Xiaoping, YAN Hong, SHANG Rong, SUN Zhina. Expression changes of serum miR-455-3p and miR-106b-5p in patients with chronic obstructive pulmonary disease and their clinical significance[J]. Laboratory Medicine, 2026, 41(8): 769-773.

Figures/Tables 7

References 19

[1]	徐丹丹. 乳酸/白蛋白比值在AECOPD患者通气治疗近期和远期预后评估中的价值[J]. 检验医学, 2025, 40(5):493-498.
[2]	Guo P, Li R, Piao T H, et al. Pathological mechanism and targeted drugs of COPD[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17:1565-1575.
[3]	崔可慧, 苏新明. 呼出气一氧化氮检测与稳定期慢性阻塞性肺疾病患者小气道改变及预后的相关性[J]. 中国医科大学学报, 2023, 52(1):12-17.
[4]	Chukowry P S, Spittle D A, Turner A M. Small airways disease,biomarkers and COPD:where are we[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16:351-365.
[5]	高健敏, 朱勇德, 符国平. 血浆miRNA-145,miRNA-183水平在慢性阻塞性肺疾病急性加重期诊断及预后评估中的应用[J]. 郑州大学学报(医学版), 2022, 57(4):491-495.
[6]	Ouyang C, Wang W, Wu D, et al. Analysis of serum exosome microRNAs in the rat model of chronic obstructive pulmonary disease[J]. Am J Transl Res, 2023, 15(1):138-150.
[7]	李菲, 李玲玲, 单武梁, 等. miR4553p调控Keap1/Nrf2信号对气道平滑肌细胞凋亡的机制研究[J]. 解剖学研究, 2023, 45(4):314-321.
[8]	Wang R, Xu J, Liu H, et al. Peripheral leukocyte microRNAs as novel biomarkers for COPD[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12:1101-1112.
[9]	国家卫生健康委员会急诊医学质控中心, 中华医学会急诊医学分会, 中国医师协会急诊医师分会, 等. 中国慢性阻塞性肺疾病急性加重中西医诊治专家共识(2021)[J]. 中华危重病急救医学, 2021, 33(11):1281-1290.
[10]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3):170-205.
[11]	马大文, 王宏俊, 胡莎莎. NLR、PLR联合MPV预测老年慢性阻塞性肺疾病患者急性加重期近期预后不良的价值[J]. 检验医学, 2022, 37(9):850-854.
[12]	Christenson S A, Smith B M, Bafadhel M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342):2227-2242.
[13]	Mathioudakis A G, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease:in search of diagnostic biomarkers and treatable traits[J]. Thorax, 2020, 75(6):520-527.
[14]	白燕, 辜依海, 刘玥彤, 等. 慢性阻塞性肺疾病患者血清Clara细胞分泌蛋白16、人中性粒细胞多肽表达及临床意义[J]. 临床误诊误治, 2023, 36(3):54-58.
[15]	He H, Wang J, Zhang Y, et al. MiR-455-3p regulates lymphangiogenesis in silicosis by regulating VEGF-C/VEGFR3[J]. Ecotoxicol Environ Saf, 2024, 278:16444.
[16]	Liu P, Zhao L, Gu Y, et al. LncRNA SNHG16 promotes pulmonary fibrosis by targeting miR-455-3p to regulate the Notch2 pathway[J]. Respir Res, 2021, 22(1):44.
[17]	Wang Z, Li T E, Chen M, et al. MiR-106b-5p contributes to the lung metastasis of breast cancer via targeting CNN1 and regulating Rho/ROCK1 pathway[J]. Aging (Albany NY), 2020, 12(2):1867-1887.
[18]	任丹, 张田, 李杰. lncRNA MALAT1调节miR-106b-5p/TLR4轴对慢性阻塞性肺疾病大鼠肺组织炎性损伤的影响[J]. 中国实验诊断学, 2023, 27(11):1342-1350.
[19]	吴亚婷, 李卓林, 雷艳, 等. 尿液中miRNA作为常见恶性肿瘤生物标志物研究进展[J]. 检验医学, 2023, 38(1):94-99.

基因名称	正向引物（5'~3'）	反向引物（5'~3'）
miR-455-3p	GCAGUCCAUGGCGAUAUACAC	GUGUAUAUGCCCAUGGACUGCUU
miR-106b-5p	CTGCTGGGACTAAAGTGCTGAC	GCAGCAAGTACCCACAGTGC
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT

基因名称	正向引物（5'~3'）	反向引物（5'~3'）
miR-455-3p	GCAGUCCAUGGCGAUAUACAC	GUGUAUAUGCCCAUGGACUGCUU
miR-106b-5p	CTGCTGGGACTAAAGTGCTGAC	GCAGCAAGTACCCACAGTGC
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT

组别	例数	性别		年龄/岁	BMI/（kg·m^-2）	吸烟史/[例（%）]	饮酒史/[例（%）]	miR-455-3p	miR-106b-5p
组别	例数	男/[例（%）]	女/[例（%）]	年龄/岁	BMI/（kg·m^-2）	吸烟史/[例（%）]	饮酒史/[例（%）]	miR-455-3p	miR-106b-5p
正常对照组	90	57（63.33）	33（36.67）	62.17±7.83	23.51±2.76	39（43.33）	23（25.56）	1.02±0.19	0.98±0.16
COPD组	109	64（58.72）	45（41.28）	63.46±8.15	23.92±2.98	61（55.96）	39（35.78）	0.79±0.14	0.67±0.12
t值		0.441		1.131	0.999	3.146	2.403	9.818	15.603
P值		0.507		0.259	0.319	0.076	0.121	<0.001	<0.001

组别	例数	性别		年龄/岁	BMI/（kg·m^-2）	吸烟史/[例（%）]	饮酒史/[例（%）]	miR-455-3p	miR-106b-5p
组别	例数	男/[例（%）]	女/[例（%）]	年龄/岁	BMI/（kg·m^-2）	吸烟史/[例（%）]	饮酒史/[例（%）]	miR-455-3p	miR-106b-5p
正常对照组	90	57（63.33）	33（36.67）	62.17±7.83	23.51±2.76	39（43.33）	23（25.56）	1.02±0.19	0.98±0.16
COPD组	109	64（58.72）	45（41.28）	63.46±8.15	23.92±2.98	61（55.96）	39（35.78）	0.79±0.14	0.67±0.12
t值		0.441		1.131	0.999	3.146	2.403	9.818	15.603
P值		0.507		0.259	0.319	0.076	0.121	<0.001	<0.001

组别	例数	miR-455-3p	miR-106b-5p	FEV₁/L	FVC/L	FEV₁/FVC比值/%	PEF/（L·s^-1）
稳定期组	47	0.88±0.14	0.78±0.15	1.56±0.21	1.83±0.59	0.57±0.78	4.58±0.57
AECOPD组	62	0.72±0.12	0.59±0.11	1.13±0.16	1.51±0.37	0.40±0.06	4.13±0.72
t值		6.414	7.632	12.138	3.467	12.682	3.527
P值		<0.001	<0.001	<0.001	0.001	<0.001	0.001